prognosis, however markers that further risk-stratify intermediate groups are needed. Serum cancer antigen-125 (CA125) and human epididymis-4 (HE4) show promise as prognostic markers. The aim of this study was to evaluate the association between serum CA125, HE4 and endometrial cancer survival outcomes when stratified by molecular subgroup.

Methodology
Pre-treatment serum CA125 and HE4 levels were measured and endometrial tumours classified according to WHO molecular classification. The relationship between biomarkers and survival was evaluated using Kaplan-Meier analysis and multivariable cox regression.

Results
Overall, 327 women were included, with POLE status available for 216. Tumours were POLE-mutant (5%), p53-abnormal (11%), MMR-deficient (30%) and NSMP (54%). Median follow up was 50 months (IQR 30–60), during which 42 (13%) recurred and 71 (21%) women died. CA125≥35U/mL was independently associated with overall mortality [aHR=2.42 (95%CI:1.45–4.06), p=0.001], cancer specific death [aHR=2.00 (95%CI:1.04–3.87), p=0.04] and recurrence [aHR=2.69 (95%CI:1.38–5.27), p=0.004]. When stratified by molecular subgroup, CA125≥35U/mL and HE4≥150pmol/L were prognostic of overall survival in MMR-deficient [CA125: aHR=4.92 (95%CI:1.74–13.89), p=0.003 and HE4: aHR=4.03 (95%CI:1.34–12.11), p=0.01] and NSMP subgroups [CA125: aHR=3.72 (95%CI:1.30–10.67), p=0.01].

Conclusion
CA125 and HE4 may risk-stratify those at intermediate risk of recurrence and death. Evaluation in a larger population is required.

**2022-RA-1457-ESGO**

**GYNECOLOGICAL CANCER DETECTION USING FOURIER-TRANSFORMED INFRA-RED SPECTROSCOPY IN URINE SAMPLES: POTENTIAL AND ACCURACY OF MACHINE LEARNING PROCESSING**


**Introduction/Background** Making an early diagnosis of cancer remains a leading cause of morbidity and mortality among gynecological cancers worldwide. The emerging technique of liquid biopsy has been proposed as a method for detecting cancer in early stage using biofluids and their properties as biomarkers.

**Methodology** In this study, we tested the application of an artificial intelligence (AI) algorithm on infra-red spectra taken from urine samples from 84 female patients with gynecological cancer (28 breast, 32 endometrial, 24 ovarian and 10 cervical) and 200 non-tumor patients who were used as controls. The spectra were normalized, and outlier values were detected and removed using a DBSCAN algorithm. To overcome the possible problem of an unbalanced dataset, we used a SMOTE algorithm enhancing the generalization of the predictive model. The AI-model was trained and tested in classifying healthy urine samples vs different cancer types.

**Results** The spectra were divided into training- and testing-datasets with a ratio of 80/20 randomly + 10-fold cross validation and various classifiers were put under test: decision trees, discriminant analysis, support vector machines, logistic regression and random forest, with the latter giving the best results. In the classification report Precision-, Recall-, and F1-scores varied from 0.93 to 1.00, 0.88 to 1.00 and 0.94 to 0.99 respectively.

**Conclusion** These results confirm the reports from previous, smaller studies and show that AI-models could be useful in differentiating biofluid samples, such as urine, between patients and healthy controls. Further research is needed in order to confirm the validity of the method and to assess its potential on clinical applications.

**2022-RA-1480-ESGO**

**TRANSLACOL PROJECT: DIGITAL-PCR HUMAN PAPILLOMA VIRUS (HPV) DETECTION FOR RECURRENCE PREDICTION IN EARLY CERVICAL CANCER PATIENTS WITHOUT PELVIC LYMPH NODE INVASION**

Rosa Montero Macedas, Nicolas Robillard, Thomas Bruneau, Coronado Pluvio, Melanie Bouhlel, Marie-Aude Le Pere-Beloa, Ivanne Stanczuk, Martina Aida Angeles, Siliane Mery, Pascal Rigole, Cecile Badosiu, Patrice Marthevet, Anne-Sophie Bats, Valerie Taly, David Veyer, Fabrice Lecuru, Helene Pere, Gynecologic and Obstetrics, Simone Veil Hospital, Eaubonne, France; Virology Laboratory, European Georges Pompidou Hospital, Paris, France; Women’s Health Institute Jose Botella Lluisa, Hospital Clinico San Carlos, Fundacion de Investigacion del Hospital Clinico San Carlos (IdESC), Universidad Complutense, Madrid, Spain; Pathology Department, European Georges Pompidou Hospital, Paris, France; Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole – Institut Claudius Regaud, Toulouse, France; Pathology Department, Institut Universitaire du Cancer Toulouse Oncopole – Institut Claudius Regaud, Toulouse, France; Université Paris-Saclay, Institut Curie, CNRS UMR 9187, Inserm U1196, Orsay, France; Centre Hospitalier universitaire vaudois (CHUV), Lausanne, Switzerland; Gynecologic and Breast Oncologic Surgery Department, European Georges Pompidou Hospital, Paris, France; INSERM, Functional Genomics of Solid Tumors (FunGeST), Centre de Recherche des Cordeliers, Université de Paris and Sorbonne Université, Paris, France; Breast, gynecology and reconstructive surgery unit. Curie Institute, Paris, France

10.1136/ijgc-2022-ESGO.895

**Introduction/Background** In early cervical cancer (ECC) patients with nodal metastasis (N+) present worse survival. However, 10–15% of patients without nodal metastasis (N0) present the same survival to N+ patients. As in cervical cancer, HPV DNA could be assimilated to tumoral DNA, we evaluate the presence of HPV DNA in pelvic Sentinel lymph nodes (SLN) by new ultrasensitive droplet-based digital polymerase chain reaction (ddPCR) as a biomarker of survival.

**Methodology** Inclusion criteria: EEC patients who underwent pelvic SLN detection N0 in pelvic lymph nodes. Associated pelvic lymph nodes samples were available for 60 patients with HPV16, HPV18 or HPV33 positive tumours. In SLN, after DNA extraction, HPV16 E6, HPV18 E7 and HPV33 E6 gene were respectively targeted and detected by ultrasensitive ddPCR optimized on two different platforms, the RainDrop Digital PCR System (RainDance Technologies, Bio-Rad, Hercules, CA) or the Biorad system. We compare two groups according to HPV DNA in SLN: positive or negative.

**Results** There was no difference between the negative HPV DNA SLN group and the positive HPV DNA SLN group in terms of patients and surgical-pathological characteristics, treatments and time of follow-up. Two patients in negative HPV DNA SLN group and 6 in positive HPV DNA SLN group presented recurrence and the mean time of recurrence was...
respective 43.5 and 29.2 month, but, these differences are not statistically significant. However, all of the 4 deaths listed in our study occurred in the positive HPV DNA SLN group for which the 10 years Overall survival (OS) is thus significantly decreased.

Abstract 2022-RA-1480-ESGO Figure 1

Conclusion Our results show worst OS in patients with detected HPV DNA compared to patients without detected HPV DNA in their SLN and the same tendency is observed for PFS without significance. Thus, HPV DNA in SLN detected by ultrasensitive ddPCR could represent an interesting prognosis biomarker in N0 ECC.

MULTIPLEXED BIOMARKER DETECTION USING THE QUANTIGENE ASSAY IN WOMEN LIVING WITH HIV FOR CERVICAL DYSPLASIA DETECTION

Introduction/Background Cervical cancer (CxCa) and its precursor lesions are caused by persistent infection with a high-risk (HR) Human Papillomavirus (HPV). Women living with HIV (WLWH) have a higher risk for cervical dysplasia and CxCa development. The high HPV prevalence in WLWH makes a HPV-PCR based screening non-efficient. Biomarker detection could be a possibility, to find woman at risk. We evaluated the QG-MPH analysis.

Results HIV coinfection was significantly associated with increased mRNA expression of the following biomarkers in HR-HPV+ women without cervical lesions: leading HPV-E7 (p=0.0019), p16 (p=0.022), STMN1 (p=0.0039), MCM2 (p=0.015), KRT7 (p=0.0035) and KRT17 (p=0.014). In cervical cancer cases (HIV+=19, HIV-=18) only the expression of Nanog mRNA was different (p=0.022). Using the risk score developed on a HIV- cohort led to false positive detection (CIN3+) of 68.8% (n=22) in WLWH without lesions. Logistic regression analyses showed best markers for CxCa detection in HIV+ patients in our cohort were BIRC5, KRT17, MMP7 and p53 with a combined AUC of 0.93 (sensitivity=95%, specificity=82.0%).

Conclusion Viral oncogene expression is increased in HR-HPV + WLWH without cervical lesions. Biomarker evaluation has the potential to overcome problems of HPV PCR-based screening in WLWH. However, risk score adaptation is needed as biomarker expression varies between HIV+ and HIV-patients. Further studies with higher sample number are warranted to confirm the best markers and risk scores by QG-MPH analysis.

A COMBINATION OF MOLECULAR AND CLINICAL PARAMETERS PROVIDES A NEW STRATEGY FOR HIGH-GRADE SEROUS OVARIAN CANCER PATIENT MANAGEMENT

Introduction/Background High-grade serous carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer. Although most patients will initially respond to first-line treatment with a combination of surgery and platinum-based chemotherapy, up to a quarter will be resistant to treatment. We aimed to identify a new strategy to improve HGSC patient management at the time of cancer diagnosis (HGSC-ILTR).

Methodology Ready-available formalin-fixed paraffin-embedded HGSC tissues obtained at the time of diagnosis were selected for proteomic analysis. Clinical data, treatment approach and outcomes were collected for all patients. Chemoresistant (TFFp < 6 m) and chemosensitive (TFFp > 6 m) groups were evaluated using discovery proteomics (discovery cohort, n=21). Protein candidates were verified in independent cohorts using targeted proteomics (verification cohort, n=88). Predictive analysis combined with a cross-validation was used to select those proteins able to correctly classify patients into chemoresistant and chemosensitive groups. The classification performance of the protein and clinical data combinations were assessed through the generation of receiver operating characteristic (ROC) curves.